Literature DB >> 11561084

Neuroprotective agent riluzole dramatically slows inactivation of Kv1.4 potassium channels by a voltage-dependent oxidative mechanism.

L Xu1, J A Enyeart, J J Enyeart.   

Abstract

The modulation of Kv1.4 K+ channels by the neuroprotective agent riluzole was studied in bovine adrenal zona fasciculata cells by using whole-cell patch clamp. At concentrations ranging from 1 to 100 microM, riluzole reversibly inhibited Kv1.4 channels (IC50 = 70 microM) and irreversibly slowed Kv1.4 inactivation. Riluzole (100 microM) increased the inactivation time constant (tau(i)) from a control value of 28.9 +/- 3.9 to 623 +/- 47.6 ms (n = 13). The slowing of bKv1.4 inactivation was not affected by substituting poorly hydrolyzable nucleotides for ATP in the pipette solution, or by the addition of cAMP. Riluzole-induced slowing of bKv1.4 inactivation was nearly eliminated by the presence of the antioxidant reduced glutathione (3 mM) or dithiothreitol (3-5 mM) in the recording pipette, or when cells were superfused with riluzole at a holding potential of -40 mV rather than -80 mV. These results are consistent with a model in which riluzole inhibits bKv1.4 currents and slows inactivation by separate mechanisms. Slowing of inactivation is independent of protein kinases, but probably involves oxidation of a cysteine in the N-terminal inactivation domain. Failure of riluzole to slow inactivation when applied to a depolarized cell suggests that this cysteine is protected in an inactivated Kv1.4 channel. The neuroprotective action of riluzole involves inhibition of glutamate release from presynaptic terminals within the central nervous system. Kv1.4 K+ channels are distributed throughout the brain in axons and nerve terminals, including those from which glutamate is released. The pronounced slowing of Kv1.4 inactivation by riluzole in these neurons could be an important mechanism underlying the inhibition of glutamate release and the therapeutic actions of this drug.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11561084

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  15 in total

1.  Control of neuronal persistent activity by voltage-dependent dendritic properties.

Authors:  Erwin Idoux; Daniel Eugène; Antoine Chambaz; Christophe Magnani; John A White; Lee E Moore
Journal:  J Neurophysiol       Date:  2008-07-16       Impact factor: 2.714

2.  Kv1.5 is a major component underlying the A-type potassium current in retinal arteriolar smooth muscle.

Authors:  Mary K McGahon; Jennine M Dawicki; Aruna Arora; D A Simpson; T A Gardiner; A W Stitt; C Norman Scholfield; J Graham McGeown; Tim M Curtis
Journal:  Am J Physiol Heart Circ Physiol       Date:  2006-10-13       Impact factor: 4.733

3.  Raised nitrate concentration and low SOD activity in the CSF of sporadic ALS patients.

Authors:  Marie-Catherine Boll; Mireya Alcaraz-Zubeldia; Sergio Montes; Luis Murillo-Bonilla; Camilo Rios
Journal:  Neurochem Res       Date:  2003-05       Impact factor: 3.996

Review 4.  Oxidative modulation of voltage-gated potassium channels.

Authors:  Nirakar Sahoo; Toshinori Hoshi; Stefan H Heinemann
Journal:  Antioxid Redox Signal       Date:  2013-10-26       Impact factor: 8.401

Review 5.  Riluzole in the treatment of mood and anxiety disorders.

Authors:  Christopher Pittenger; Vladimir Coric; Mounira Banasr; Michael Bloch; John H Krystal; Gerard Sanacora
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

Review 6.  Glutamate-modulating drugs as novel pharmacotherapeutic agents in the treatment of obsessive-compulsive disorder.

Authors:  Christopher Pittenger; John H Krystal; Vladimir Coric
Journal:  NeuroRx       Date:  2006-01

7.  Riluzole Impairs Cocaine Reinstatement and Restores Adaptations in Intrinsic Excitability and GLT-1 Expression.

Authors:  Marian T Sepulveda-Orengo; Kati L Healey; Ronald Kim; Alyson C Auriemma; Jennifer Rojas; Nicholas Woronoff; Rachel Hyppolite; Kathryn J Reissner
Journal:  Neuropsychopharmacology       Date:  2017-10-09       Impact factor: 7.853

8.  Heme impairs the ball-and-chain inactivation of potassium channels.

Authors:  Nirakar Sahoo; Nishit Goradia; Oliver Ohlenschläger; Roland Schönherr; Manfred Friedrich; Winfried Plass; Reinhard Kappl; Toshinori Hoshi; Stefan H Heinemann
Journal:  Proc Natl Acad Sci U S A       Date:  2013-09-30       Impact factor: 11.205

9.  Hemopressin, an inverse agonist of cannabinoid receptors, inhibits neuropathic pain in rats.

Authors:  Elaine F Toniolo; Estêfani T Maique; Wilson A Ferreira; Andrea S Heimann; Emer S Ferro; Dinah L Ramos-Ortolaza; Lydia Miller; Lakshmi A Devi; Camila S Dale
Journal:  Peptides       Date:  2014-04-03       Impact factor: 3.750

10.  The Sur1-Trpm4 Channel in Spinal Cord Injury.

Authors:  J Marc Simard; Seung Kyoon Woo; Bizhan Aarabi; Volodymyr Gerzanich
Journal:  J Spine       Date:  2013-08-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.